A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis—a primary driver of cardiovascular death worldwide—in large mammals, a study suggests.

the Multi-Ethnic Study of Atherosclerosis (MESA). The goal of yielding information essential for setting priorities informing prevention efforts will be achieved by observing changes in subclinical ...